EN
CN EN
SUYA-HBIV
Human Hepatitis B Immunoglobulin (pH4) for Intravenous Injection
Name
Human Hepatitis B Immunoglobulin (pH4) for Intravenous Injection
Use within
36 months
Specifications
Each vial contains 2000IU (40ml) anti-HBs.
Approval Number
SFDA Approval No. S20083007
Indications
Combination with lamivudine for the prevention of hepatitis B virus (HBV) re-infection in liver transplant patients.